Result of AGM
27/06/2022 13:58
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220627:nRSa3317Qa&default-theme=true
RNS Number : 3317Q Medica Group PLC 27 June 2022
27 June 2022
Medica Group Plc
Result of Annual General Meeting
Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland
market leader in the provision of teleradiology services, announces that, at
its Annual General Meeting held at 11.00am today, all resolutions put to the
meeting were duly passed.
Details of the voting are as follows:
Resolution For/ % Against % Total Withheld
Discretion For/ (Number of votes) Against votes (Number of votes)
(Number of Discretion
votes)
Ordinary Business
1. To receive and adopt the annual report, accounts and the auditor's report
100,735,575
100.00
0
0.00
100,735,575
1,173,666
2. To approve the Directors' Remuneration Report (excluding Remuneration Policy)
100,703,036
99.72
279,222
0.28
100,982,258
926,983
3. To approve the amendments to the rules of the Performance Share Plan
100,165,535
99.19
814,918
0.81
100,980,453
928,788
4. To declare a final dividend
100,985,486
100.00
0
0.00
100,985,486
923,755
5. To re-appoint Grant Thornton UK LLP as auditors
100,731,909
99.995
4,728
0.005
100,736,637
1,172,604
6. To authorise the directors to determine the remuneration of the auditors
100,981,201
100,981,201
928,040
100.00 0 0.00
7. To re-elect Roy Davis as a Director
101,032,592
99.21
807,948
0.79
101,840,540
68,701
8. To re-elect Joanne Easton as a Director
101,516,659
99.67
340,582
0.33
101,857,241
52,000
9. To re-elect Dr Junaid Bajwa as a Director
99,013,524
97.97
2,048,111
2.03
101,061,635
847,606
10. To re-elect Stuart Quin as a Director
101,834,429
99.98
20,355
0.02
101,854,784
54,457
11. To re-elect Richard Jones as a Director
101,602,107
99.998
2,028
0.002
101,604,135
305,106
12. To elect Barbara Moorhouse as a Director
101,850,479
101,850,479
58,762
100.00 0 0.00
Special Business
13. General authority to allot shares pursuant to Section 551 Companies Act 2006
100,912,668
99.93
68,956
0.07
100,981,624
927,617
14. General authority to allot equity securities pursuant to Section 570 Companies
Act 2006
94,241,011
93.32
6,742,613
6.68
100,983,624
925,617
15. General authority to allot equity securities pursuant to Section 570 Companies
Act 2006 for the purpose of financing an acquisition or other capital
94,240,212
93.32
6,742,717
6.68
100,982,929
926,312
investment
16. Authority to make market purchases of up to 12,242,883 shares
100,680,388
99.75
253,649
0.25
100,934,037
975,204
17. To authorise the general meeting to be held on 14 clear days' notice
100,117,101
99.14
867,690
0.86
100,984,791
924,450
100.00
0
0.00
100,735,575
1,173,666
2.
To approve the Directors' Remuneration Report (excluding Remuneration Policy)
100,703,036
99.72
279,222
0.28
100,982,258
926,983
3.
To approve the amendments to the rules of the Performance Share Plan
100,165,535
99.19
814,918
0.81
100,980,453
928,788
4.
To declare a final dividend
100,985,486
100.00
0
0.00
100,985,486
923,755
5.
To re-appoint Grant Thornton UK LLP as auditors
100,731,909
99.995
4,728
0.005
100,736,637
1,172,604
6.
To authorise the directors to determine the remuneration of the auditors
100,981,201
100.00
0
0.00
100,981,201
928,040
7.
To re-elect Roy Davis as a Director
101,032,592
99.21
807,948
0.79
101,840,540
68,701
8.
To re-elect Joanne Easton as a Director
101,516,659
99.67
340,582
0.33
101,857,241
52,000
9.
To re-elect Dr Junaid Bajwa as a Director
99,013,524
97.97
2,048,111
2.03
101,061,635
847,606
10.
To re-elect Stuart Quin as a Director
101,834,429
99.98
20,355
0.02
101,854,784
54,457
11.
To re-elect Richard Jones as a Director
101,602,107
99.998
2,028
0.002
101,604,135
305,106
12.
To elect Barbara Moorhouse as a Director
101,850,479
100.00
0
0.00
101,850,479
58,762
Special Business
13.
General authority to allot shares pursuant to Section 551 Companies Act 2006
100,912,668
99.93
68,956
0.07
100,981,624
927,617
14.
General authority to allot equity securities pursuant to Section 570 Companies
Act 2006
94,241,011
93.32
6,742,613
6.68
100,983,624
925,617
15.
General authority to allot equity securities pursuant to Section 570 Companies
Act 2006 for the purpose of financing an acquisition or other capital
investment
94,240,212
93.32
6,742,717
6.68
100,982,929
926,312
16.
Authority to make market purchases of up to 12,242,883 shares
100,680,388
99.75
253,649
0.25
100,934,037
975,204
17.
To authorise the general meeting to be held on 14 clear days' notice
100,117,101
99.14
867,690
0.86
100,984,791
924,450
For further information, please contact:
Medica Group Plc: +44 (0)33 33 111 222
Stuart Quin, Chief Executive Officer
Richard Jones, Chief Financial Officer
FTI Consulting +44 (0)20 3727 1000
Victoria Foster Mitchell
Sam Purewal
Liberum (Joint Broker) +44 (0)20 3100 2000
Phil Walker
Richard Lindley
Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield
Duncan Monteith
Euan Brown
About Medica Group PLC
Medica is the market leader in the UK and Ireland for the provision of
teleradiology services, providing outsourced interpretation and reporting of
MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and
plain film (x-ray) images. Medica also offers diabetic retinopathy screening
in Ireland.
Medica contracts with the largest pool of consultant radiologists in the UK
and Ireland, performing remote access teleradiology across its customer base
of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and
insurance groups, as well as diagnostic imaging companies. This enables the
Company to offer a fast, responsive service. In addition, Medica operates in
Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral
Diagnostics Limited Pty.
The Company currently offers two primary services to hospital radiology
departments:
· NightHawk - urgent reporting service
· Elective - includes routine cross-sectional reporting on MRI and
CT scans, and routine plain film reporting on x-ray images.
These services are underpinned by Medica's bespoke, secure IT platform that
provides market-leading linkage between a hospital's Radiology Information
System (RIS) and consultant radiologists who contract with the Company. Direct
RIS access ensures that where the wider patient medical history is available,
it can be reviewed by the consultant as part of every report.
Through its subsidiary, RadMD, in the United States, Medica also provides
pharmaceutical and biotech clients and contract research organisations (CROs)
with high quality, complex imaging services for international clinical trials.
RadMD has gained vast experience in the space, having contributed to over 500
international clinical trials, in all phases of clinical research from proof
of concept to phase III and with expertise in oncology, as well as a wider
range of therapeutic areas including medical devices, neurology and
cardiovascular.
For more information please visit: www.medicagroupplc.com
(http://www.medicagroupplc.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGEAAKXASKAEFA